Aura Biosciences, Inc. Common Stock AURA
i
Market datapartial · fetched 2026-11-18T01:20:51.765Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-17T21:00:00.16217937Z
FundamentalsAlpha Vantage · unavailable
Aura Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 8.16 | 165.1% | 20.8% | |||
| 50Δ | 8.43 | 148.2% | 17.1% | |||
| 55Δ | 8.70 | 131.3% | 13.3% | |||
| 60Δ | 8.96 | 114.4% | 9.6% | |||
| 65Δ | ||||||
| 70Δ | 6.58 | 200.0% | 26.6% | |||
| 75Δ | 5.83 | 168.5% | 16.5% | |||
| 80Δ | 5.41 | 140.2% | 10.6% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.16
- IV
- 165.1%
- B/E move
- 20.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.43
- IV
- 148.2%
- B/E move
- 17.1%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.70
- IV
- 131.3%
- B/E move
- 13.3%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.96
- IV
- 114.4%
- B/E move
- 9.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
70Δ
- Pseudo strike
- 6.58
- IV
- 200.0%
- B/E move
- 26.6%
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- 5.83
- IV
- 168.5%
- B/E move
- 16.5%
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- 5.41
- IV
- 140.2%
- B/E move
- 10.6%
- Pseudo strike
- IV
- B/E move
Options history
History unavailable
Biotechnology
AUTL
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T-cell therapies for the treatment of cancer. The company is headquartered in London, the United…
More →AVBP
ArriVent BioPharma, Inc. (AVBP) is a dynamic biopharmaceutical company dedicated to developing pioneering therapies that address critical unmet needs in oncology and autoimmune…
More →AVIR
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapies for patients suffering from viral…
More →AVLN
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for severe respiratory diseases, with its lead candidate, AV-101,…
More →AVTX
Description unavailable
More →AVXL
Description unavailable
More →